Plasminogen Activator Inhibitor Type 2 in Breast Cancer
Author Information
Author(s): C Duggan, S Kennedy, MD Kramer, C Barnes, P EIvin, E McDermott, N O'Higgins, MJ Duffy
Hypothesis
The study aims to investigate the levels of PAI-2 in different types of breast tumors and relate its levels to other components of the plasminogen activator system, pathological characteristics of the tumors, and patient outcomes.
Conclusion
High levels of PAI-2 may be a favorable prognostic marker in breast cancer, particularly in certain subgroups of patients.
Supporting Evidence
- PAI-2 levels were significantly higher in primary breast carcinomas than in benign breast tumors.
- Patients with low levels of PAI-2 had a worse outcome than those with high levels.
- PAI-2 levels correlated weakly but significantly with PAI-1 and uPA levels.
Takeaway
This study found that higher levels of a protein called PAI-2 in breast cancer might mean a better chance of recovery for some patients.
Methodology
The study used enzyme-linked immunosorbent assay (ELISA) to measure PAI-2 levels in tumor samples and analyzed correlations with patient outcomes.
Limitations
The study did not find significant relationships between PAI-2 levels and established prognostic markers like tumor size and nodal status.
Participant Demographics
{"age":{"under_50":68,"over_50":84},"tumor_size":{"under_2cm":39,"between_2_and_5cm":61,"over_5cm":25},"nodal_status":{"negative":62,"positive":63},"estrogen_receptor_status":{"positive":87,"negative":57}}
Statistical Information
P-Value
0.0315
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website